Back

touchIME, USF Health

  • Carcinoma, Non-Small-Cell Lung

Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers

Integrate biomarker testing into clinical workflows and prioritize appropriate testing in EGFR-mutant NSCLC to guide clinical decision making

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 2.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 2.25 credits
  • Released
    Jan 15, 2026
  • Last day to claim credit
    Jan 16, 2027 3 months left